These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16170173)

  • 21. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
    Chiorean EG; Porter JM; Foster AE; Al Omari AS; Yoder CA; Fife KL; Strother RM; Murry DJ; Yu M; Jones DR; Sweeney CJ
    Clin Cancer Res; 2008 Feb; 14(4):1131-7. PubMed ID: 18281547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
    Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
    Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bexarotene and erlotinib for aerodigestive tract cancer.
    Dragnev KH; Petty WJ; Shah S; Biddle A; Desai NB; Memoli V; Rigas JR; Dmitrovsky E
    J Clin Oncol; 2005 Dec; 23(34):8757-64. PubMed ID: 16314636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
    Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA
    Cancer; 2006 Sep; 107(5):1034-41. PubMed ID: 16878326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
    Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
    J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Stuart K; Blaszkowsky LS; Muzikansky A; Reitberg DP; Clark JW; Enzinger PC; Bhargava P; Meyerhardt JA; Horgan K; Fuchs CS; Ryan DP
    Cancer; 2007 Aug; 110(3):581-9. PubMed ID: 17583545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
    J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
    Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
    J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
    Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
    Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
    J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
    Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
    Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
    Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
    Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
    Ranson M; Shaw H; Wolf J; Hamilton M; McCarthy S; Dean E; Reid A; Judson I
    Cancer Chemother Pharmacol; 2010 May; 66(1):53-8. PubMed ID: 19956953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
    N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
    Lind JS; Lagerwaard FJ; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.